ARCT · Arcturus Therapeutics
AI read · Neutral
The AI's read
The study steps give Arcturus more room to pursue its rare-disease programs, but the call reports no results showing the treatments work. It regained vaccine rights, yet revenue fell after CSL's exit. Its reported cash runway helps cushion the change, leaving the overall outlook unchanged.